Peptide approval status in Australia
Where each of the 68 compounds stands in Australia, from the TGA’s register and the Poisons Standard (October 2026), checked October 7, 2026.
This summarizes approval status. It isn’t legal advice: rules on importing, prescribing and possessing medicines differ and change. “No marketing authorization” means no approved product was found, nothing more.
- SemaglutideApproved drug
- Prescription only (Schedule 4). Registered as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management, including teens 12 and older.
- TirzepatideApproved drug
- Prescription only (Schedule 4). Mounjaro is registered for type 2 diabetes (December 2022) and weight management (September 2024). Dispensing labels must warn against use in pregnancy.
- RetatrutideHuman studies
- No marketing authorization, and retatrutide isn’t named in the Poisons Standard (October 2026). Victoria’s health department warned against unapproved retatrutide products in June 2026.
- CagrilintideHuman studies
- No product registered, and cagrilintide isn’t named in the Poisons Standard (October 2026).
- AOD9604Human studies
- Prescription only (Schedule 4), and possessing it without a prescription or other authority is illegal (Appendix D). No product is approved.
- 5-Amino-1MQPreclinical
- Not named in the Poisons Standard (October 2026); no product is approved.
- SLU-PP-332Preclinical
- Not named in the Poisons Standard (October 2026); no product is approved.
- L-CarnitineApproved drug
- Not named in the Poisons Standard (October 2026). Oral carnitine products appear on the ARTG as listed (low-risk) medicines; no registered injection was confirmed.
- HGH Fragment 176-191Preclinical
- Not named in the Poisons Standard (October 2026), unlike AOD-9604, which is prescription only with possession restricted. No product is approved.
- LiraglutideApproved drug
- Prescription only (Schedule 4). Saxenda (2015) and four generic brands are approved for adult weight management; Victoza no longer has current Australian product information.
- ExenatideApproved drug
- Schedule 4, but no exenatide product has current Australian product information; Bydureon’s registrations were canceled at the sponsor’s request.
- SurvodutideHuman studies
- No marketing authorization, and survodutide isn’t named in the Poisons Standard (October 2026).
- MazdutideApproved drug
- No marketing authorization, and mazdutide isn’t named in the Poisons Standard (October 2026).
- OrforglipronApproved drug
- No product registered. Orforglipron isn’t named in the Poisons Standard (October 2026), and the TGA lists no product information for it.
- TesofensineHuman studies
- Not named in the Poisons Standard (October 2026); no product is approved.
- NAD+Human studies
- Not named in the Poisons Standard (October 2026); no registered NAD+ medicine was confirmed.
- MOTS-cPreclinical
- No marketing authorization. MOTS-c isn’t named in the Poisons Standard (October 2026).
- SS-31Approved drug
- No marketing authorization; elamipretide isn’t named in the Poisons Standard (October 2026).
- GlutathioneApproved drug
- Glutathione for injection is prescription only (Schedule 4) in the Poisons Standard (October 2026).
- EpithalonPreclinical
- No marketing authorization; FDA’s 2026 review found no approved product. Epitalon isn’t named in the Poisons Standard (October 2026).
- HumaninPreclinical
- No marketing authorization. Humanin isn’t named in the Poisons Standard (October 2026).
- FOXO4-DRIPreclinical
- No marketing authorization. FOXO4-DRI isn’t named in the Poisons Standard (October 2026).
- BPC-157Preclinical
- Prescription only (Schedule 4) since June 1, 2024, and possessing it without a prescription or other authority is illegal (Appendix D). No product is approved.
- TB-500Preclinical
- Prescription only (Schedule 4), and possessing it without a prescription or other authority is illegal (Appendix D), per the October 2026 Poisons Standard. No product is approved.
- KPVPreclinical
- No marketing authorization, and KPV isn’t named in the Poisons Standard (October 2026), unlike BPC-157 and TB-500.
- ARA-290Human studies
- No marketing authorization. Cibinetide isn’t named in the Poisons Standard (October 2026), though erythropoietins as a class are prescription only.
- CartalaxPreclinical
- No marketing authorization. Cartalax isn’t named in the Poisons Standard (October 2026).
- MGFPreclinical
- No marketing authorization. MGF isn’t named in the Poisons Standard (October 2026), which lists insulin-like growth factors as prescription only (Schedule 4), with possession controls.
- PEG-MGFPreclinical
- No marketing authorization. PEG-MGF isn’t named in the Poisons Standard (October 2026), which lists insulin-like growth factors as prescription only (Schedule 4), with possession controls.
- Thymosin Beta-4Human studies
- Prescription only (Schedule 4), and possessing it without a prescription or other authority is illegal (Appendix D), per the October 2026 Poisons Standard. No product is approved.
- LarazotideHuman studies
- No marketing authorization. Larazotide isn’t named in the Poisons Standard (October 2026).
- CJC-1295 (no DAC)Preclinical
- Prescription only (Schedule 4): CJC-1295 is named, and growth hormone releasing hormones are listed as a group. Possessing it without authority is illegal (Appendix D). No product is approved.
- CJC-1295 with DACHuman studies
- Prescription only (Schedule 4): CJC-1295 is named, and growth hormone releasing hormones are listed as a group. Possessing it without authority is illegal (Appendix D). No product is approved.
- IpamorelinHuman studies
- Prescription only (Schedule 4), named individually and covered as a growth hormone secretagogue. Possessing it without authority is illegal (Appendix D). No product is approved.
- SermorelinHuman studies
- Prescription only (Schedule 4), named individually and covered as a growth hormone releasing hormone. Possessing it without authority is illegal (Appendix D). No marketing authorization.
- TesamorelinApproved drug
- No marketing authorization. Not named in the Poisons Standard, but growth hormone releasing hormones are Schedule 4 (prescription only) and Appendix D: possession without authority is illegal.
- IGF-1 LR3Preclinical
- No marketing authorization. Not named in the Poisons Standard, but insulin-like growth factors are Schedule 4 (prescription only) and Appendix D: possession without authority is illegal.
- GHRP-2Approved drug
- Prescription only (Schedule 4), listed as pralmorelin (GHRP-2), and possessing it without a prescription or other authority is illegal (Appendix D). No product is registered.
- GHRP-6Human studies
- Prescription only (Schedule 4), named as GHRP-6, and possessing it without a prescription or other authority is illegal (Appendix D). No product is registered.
- HexarelinHuman studies
- Prescription only (Schedule 4), named as hexarelin, and possessing it without a prescription or other authority is illegal (Appendix D). No product is registered.
- MK-677Human studies
- Prescription only (Schedule 4), named as ibutamoren, and possessing it without a prescription or other authority is illegal (Appendix D). No product is registered.
- IGF-1 DESPreclinical
- No marketing authorization. Not named in the Poisons Standard, but insulin-like growth factors are Schedule 4 (prescription only) and Appendix D: possession without authority is illegal.
- Follistatin-344Preclinical
- Prescription only (Schedule 4), named individually, and possessing it without a prescription or other authority is illegal (Appendix D). No product is approved.
- GHK-CuHuman studies
- No marketing authorization; GHK-Cu isn’t named in the Poisons Standard (October 2026). Its general copper-compounds entries exempt skin products with 5% or less, covering typical cosmetics.
- AHK-CuPreclinical
- No marketing authorization; AHK-Cu isn’t named in the Poisons Standard (October 2026). Its general copper-compounds entries exempt skin products with 5% or less, covering typical serums.
- SNAP-8Human studies
- No marketing authorization, and it isn’t named in the Poisons Standard (October 2026).
- Melanotan 1Approved drug
- Prescription only (Schedule 4). Scenesse implant is registered for adults with EPP; tanning products containing it are unapproved.
- Melanotan 2Human studies
- Prescription only (Schedule 4) under the Poisons Standard (October 2026); no product is registered.
- ArgirelineHuman studies
- No marketing authorization, and it isn’t named in the Poisons Standard (October 2026).
- MatrixylHuman studies
- No marketing authorization, and it isn’t named in the Poisons Standard (October 2026).
- hCGApproved drug
- Prescription only (Schedule 4). The TGA’s product information database lists only Ovidrel (recombinant hCG), for fertility treatment.
- Kisspeptin-10Human studies
- No registered product, and kisspeptin isn’t named in the Poisons Standard (October 2026).
- PT-141Approved drug
- No registered product. Bremelanotide isn’t named in the Poisons Standard (October 2026); the related melanotan II is prescription only (Schedule 4).
- OxytocinApproved drug
- Prescription only (Schedule 4); only very dilute preparations are exempt. Registered injections include Syntocinon, Viatocinon and generic oxytocin, plus Syntometrine (with ergometrine).
- GonadorelinApproved drug
- Prescription only (Schedule 4). The TGA publishes no product information for a human gonadorelin medicine.
- TriptorelinApproved drug
- Prescription only (Schedule 4). Registered as Diphereline depot injections (3.75 and 22.5 mg) and Decapeptyl daily injections for IVF (2015).
- SelankApproved drug
- No marketing authorization. Selank isn’t named in the Poisons Standard (October 2026).
- SemaxApproved drug
- No marketing authorization. Semax isn’t named in the Poisons Standard (October 2026).
- AdamaxPreclinical
- No marketing authorization. Adamax isn’t named in the Poisons Standard (October 2026).
- DSIPApproved drug
- No marketing authorization. DSIP isn’t named in the Poisons Standard (October 2026).
- CerebrolysinApproved drug
- No marketing authorization. Cerebrolysin isn’t named in the Poisons Standard (October 2026).
- PinealonPreclinical
- No marketing authorization. Pinealon isn’t named in the Poisons Standard (October 2026).
- DihexaHuman studies
- No marketing authorization. Dihexa isn’t named in the Poisons Standard (October 2026).
- PE-22-28Preclinical
- No marketing authorization. PE-22-28 isn’t named in the Poisons Standard (October 2026).
- Thymosin Alpha-1Approved drug
- No marketing authorization. Thymosin alpha-1 isn’t named in the Poisons Standard (October 2026); thymosin beta-4, a different peptide, is prescription only.
- ThymalinApproved drug
- No marketing authorization. Neither thymalin nor thymus extract is named in the Poisons Standard (October 2026).
- VIPApproved drug
- Aviptadil is prescription only (Schedule 4) in the Poisons Standard (October 2026). No marketing authorization for a VIP product.
- LL-37Human studies
- No marketing authorization, and LL-37 isn’t named in the Poisons Standard (October 2026) under that name, cathelicidin or ropocamptide.